Efficacy of a high potency O1 Manisa monovalent vaccine against heterologous challenge with foot-and-mouth disease virus of O/SEA/Mya-98 lineage in sheep

doi:10.1016/j.antiviral.2017.07.020

Title: Efficacy of a high potency O1 Manisa monovalent vaccine against heterologous challenge with foot-and-mouth disease virus of O/SEA/Mya-98 lineage in sheep

Full Record
Other Related Research

Authors:: Singanallur, N. B.; Pacheco, J. M.; Arzt, J.; Stenfeldt, C.; Fosgate, G. T.; Rodriguez, L.; Vosloo, W.

Publication Date:: 2017-09-01

Sponsoring Org.:: USDOE

OSTI Identifier:: 1549806

Resource Type:: Publisher's Accepted Manuscript

Journal Name:: Antiviral Research

Additional Journal Information:: [Journal Name: Antiviral Research Journal Volume: 145 Journal Issue: C]; Journal ID: ISSN 0166-3542

Publisher:: Elsevier

Country of Publication:: Netherlands

Language:: English

Citation Formats


                    Singanallur, N. B., Pacheco, J. M., Arzt, J., Stenfeldt, C., Fosgate, G. T., Rodriguez, L., and Vosloo, W. Efficacy of a high potency O1 Manisa monovalent vaccine against heterologous challenge with foot-and-mouth disease virus of O/SEA/Mya-98 lineage in sheep.  Netherlands: N. p., 2017. 
        Web.  doi:10.1016/j.antiviral.2017.07.020.

Copy to clipboard


                    Singanallur, N. B., Pacheco, J. M., Arzt, J., Stenfeldt, C., Fosgate, G. T., Rodriguez, L., & Vosloo, W. Efficacy of a high potency O1 Manisa monovalent vaccine against heterologous challenge with foot-and-mouth disease virus of O/SEA/Mya-98 lineage in sheep.  Netherlands.  doi:10.1016/j.antiviral.2017.07.020.

Copy to clipboard


                    Singanallur, N. B., Pacheco, J. M., Arzt, J., Stenfeldt, C., Fosgate, G. T., Rodriguez, L., and Vosloo, W. Fri .  
        "Efficacy of a high potency O1 Manisa monovalent vaccine against heterologous challenge with foot-and-mouth disease virus of O/SEA/Mya-98 lineage in sheep".  Netherlands.  doi:10.1016/j.antiviral.2017.07.020.

Copy to clipboard


                    
@article{osti_1549806,

  title        = {Efficacy of a high potency O1 Manisa monovalent vaccine against heterologous challenge with foot-and-mouth disease virus of O/SEA/Mya-98 lineage in sheep},

  author       = {Singanallur, N. B. and Pacheco, J. M. and Arzt, J. and Stenfeldt, C. and Fosgate, G. T. and Rodriguez, L. and Vosloo, W.},

  abstractNote = {},

  doi          = {10.1016/j.antiviral.2017.07.020},

  journal      = {Antiviral Research},

  number       = [C],

  volume       = [145],

  place        = {Netherlands},

  year         = {2017},

  month        = {9}

}

Copy to clipboard

Journal Article:

Free Publicly Available Full Text

Accepted Manuscript (Publisher)

Publisher's Version of Record
DOI: 10.1016/j.antiviral.2017.07.020

Other availability

Search WorldCat to find libraries that may hold this journal

Citation Metrics:

Cited by: 1 work

Citation information provided by
Web of Science

Save / Share:

Export Metadata

Save to My Library

Similar Records in DOE PAGES and OSTI.GOV collections:

Multiple efficacy studies of an adenovirus-vectored foot-and-mouth disease virus serotype A24 subunit vaccine in cattle using homologous challenge

Journal Article Schutta, Christopher ; Barrera, José ; Pisano, Melia ; ... - Vaccine

Here, the safety and efficacy of an experimental, replication-deficient, human adenovirus-vectored foot-and-mouth disease virus (FMDV) serotype A24 Cruzeiro capsid-based subunit vaccine (AdtA24) was examined in eight independent cattle studies. AdtA24 non-adjuvanted vaccine was administered intramuscularly to a total of 150 steers in doses ranging from approximately 1.0 × 10 ⁸ to 2.1 × 10 ¹¹ particle units per animal. No detectable local or systemic reactions were observed after vaccination. At 7 days post-vaccination (dpv), vaccinated and control animals were challenged with FMDV serotype A24 Cruzeiro via the intradermal lingual route. Vaccine efficacy was measured by FMDV A24 serum neutralizing titersmore »« less
Cited by 12
DOI: 10.1016/j.vaccine.2015.12.018
Clinical and virological dynamics of a serotype O 2010 South East Asia lineage foot-and-mouth disease virus in sheep using natural and simulated natural inoculation and exposure systems

Journal Article Stenfeldt, Carolina ; Pacheco, Juan M. ; Singanallur, Nagendrakumar B. ; ... - Veterinary Microbiology
Cited by 7
DOI: 10.1016/j.vetmic.2015.04.004
Versatility of the adenovirus-vectored foot-and-mouth disease vaccine platform across multiple foot-and-mouth disease virus serotypes and topotypes using a vaccine dose representative of the AdtA24 conditionally licensed vaccine

Journal Article Barrera, José ; Brake, David A. ; Schutta, Christopher ; ... - Vaccine

We investigated the serotype- and topotype versatility of a replication-deficient human adenovirus serotype 5 vectored foot-and-mouth disease (FMD) vaccine platform (AdtFMD). Sixteen AdtFMD recombinant subunit monovalent vaccines targeting twelve distinct FMD virus (FMDV) serotype/topotypes in FMD Regional Pools I-VII were constructed. The AdtA24 serotype conditionally licensed vaccine served as the basis for vaccine design and target dose for cattle clinical trials. Several vaccines contained an additional RGD motif genetic insertion in the adenovector fiber knob, and/or a full-length 2B gene insertion in the FMDV P1 gene cassette. In 13 of the 22 efficacy studies conducted, naïve control and AdtFMD vaccinatedmore »« less
Cited by 1
DOI: 10.1016/j.vaccine.2018.10.031

Full Text Available
Adenovirus-vectored foot-and-mouth disease vaccine confers early and full protection against FMDV O1 Manisa in swine

Journal Article Fernandez-Sainz, Ignacio ; Medina, Gisselle N. ; Ramirez-Medina, Elizabeth ; ... - Virology
Cited by 5
DOI: 10.1016/j.virol.2016.12.021
Use of ENABL® adjuvant to increase the potency of an adenovirus-vectored foot-and-mouth disease virus serotype A subunit vaccine

Journal Article Barrera, José ; Schutta, Christopher ; Pisano, Melia ; ... - Vaccine

A foot-and-mouth disease (FMD) recombinant subunit vaccine formulated with a lipid/polymer adjuvant was evaluated in two vaccine efficacy challenge studies in steers. The vaccine active ingredient is a replication-deficient human adenovirus serotype 5 vector encoding the FMD virus (FMDV) A24/Cruzeiro/BRA/55 capsid (AdtA24). In the first study, AdtA24 formulated in ENABL® adjuvant was compared to a fourfold higher dose of AdtA24 without adjuvant. Steers vaccinated with AdtA24 + ENABL® adjuvant developed a significantly higher virus neutralizing test (VNT) antibody titer and an improved clinical response following FMDV A24/Cruzeiro/BRA/55 intradermal lingual challenge at 14 days post-vaccination (dpv) than steers vaccinated with themore »« less
Cited by 6
DOI: 10.1016/j.vaccine.2018.01.026

Full Text Available

Similar Records